The Tata Memorial Centre (TMC) is a Comprehensive Cancer Centre with a mission to achieve the highest standards in patient care, cancer prevention, cancer research and professional development for oncology and allied disciplines. TMC is an autonomous body funded, controlled by the Department of Atomic Energy, Government of India. TMC is affiliated to Homi Bhabha National Institute (HBNI). The HBNI is a Deemed University of the Department of Atomic Energy with a mission to develop high quality postgraduate educational programs in science and technology including those related to life and health sciences.
Eligible and interested candidates are invited to attend the Walk-In Interview at Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U Campus, Varanasi, Uttar Pradesh – 221005. Candidates must bring Bio-data (Resume), Recent passport size photograph, PAN card, Aadhar card, Educational Certificates, Experience certificates in original and one set of self-attested copies, on the interview date(s).
Junior Research Fellow (Non-Medical)
No. of Vacancy : 01 (one)
Walk-In Interview Date : Monday, 23.06.2025
Monthly Remuneration : Rs. 40,000/- to Rs. 45,000/-
Eligibility Criteria : Post-Graduation in life science.
Project Name & A/c No. : Palliative Triple Oral Metronomic Therapy and Low-Dose Nivolumab with or without Hypo fractionated Radiotherapy: A randomized Phase III Trial (PALLADIUM Trial) (Project A/c No. 160039)
Clinical Trial Coordinator
No. of Vacancy : 07 (seven)
Walk-In Interview Date : Saturday, 21.06.2025
Monthly Remuneration : Rs. 25,000/- to Rs. 35,000/-
Eligibility Criteria : Graduate degree in science with PG Diploma in Clinical Research.
Experience of one year in relevant filed is desirable.
Project Name & A/c No. :
(i) IM Project-TRAC (Project A/c 9221) (01-Post)
(ii) A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. (Project A/c 9490) (01-Post)
(iii) PACIFIC-08: A phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose disease has not progressed following definitive Platinum-based Concurrent Chemo radiation Therapy. (Project A/c No. 160009) (01-Post) (iv) Study Code D9673L00012: A Prospective, Multi-Center, Phase 4, Single Arm Study to assess the safety of Transtuzumab Deruxtecan, an Anti-her2-antibody drug conjugate in Indian patients with unresectable or metastatic her2-based regimen. (Project A/c No. 180003) (01-Post)
(v) A randomized, double blind, parallel-group study to Compare efficacy, safety, and immunogenicity of GME751 (proposed pembrolizumab biosimilar) and EU- authorized Keytruda® in adult participants with untreated metastatic non- squamous non-small cell lung cancer (NSCLC). (Project A/c No. 160011) (01- Post) (vi) SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression. (Project A/c No. 160025) (01-Post)
(vii) A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CKD4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPltello-292) (Project A/c No. 9256) (01-Post)
Research Assistant
No. of Vacancy : 01 (one)
Walk-In Interview Date : Wednesday, 25.06.2025
Monthly Remuneration : Rs. 23,000/-
Eligibility Criteria : Graduate degree in science.
Project Name & A/c No. : Academic Fund (Project A/c No. 9299)
Note
1. The tenure will be valid for six months and may be extended further based on satisfactory performance and the institute’s requirement.
2. If there are many applicants, an MCQ test will be conducted as a shortlisting criterion, and only eligible candidates will be invited for the interview accordingly.
3. Outstation candidates are advised that accommodation will not be provided.
Walk-In Interview at Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U Campus, Varanasi, Uttar Pradesh – 221005.
Reporting time : 09:00 A.M. to 10:00 A.M.
See All Varanasi Alerts B.Pharm Alerts D.Pharm Alerts M.Sc Alerts
See All Other Jobs in our Database
Subscribe to Pharmatutor Job Alerts by Email
